Beta-Lactamase Inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Beta-Lactamase Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Beta-Lactamase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Beta-Lactamase Inhibitor: Overview
Beta-lactamases are an important group of bacterial enzymes, which preferentially cleave the beta-lactam ring of penicillins, cephalosporins, or other medically important beta-lactam antibiotics.
Function - Beta-lactamase provides antibiotic resistance by breaking the antibiotics' structure. These antibiotics all have a common element in their molecular structure: a four-atom ring known as a ?-lactam. Through hydrolysis, the enzyme lactamase breaks the ?-lactam ring open, deactivating the molecule's antibacterial properties.
Beta-Lactamase Inhibitors - Beta-lactamase inhibitors are drugs that are co-administered with beta-lactam antimicrobials to prevent antimicrobial resistance by inhibiting serine beta-lactamases, which are enzymes that inactivate the beta-lactam ring, which is a common chemical structure to all beta-lactam antimicrobials. This activity outlines the different types of beta-lactamase inhibitors.
Beta-Lactamase Inhibitor Emerging Drugs Chapters
This segment of the Beta-Lactamase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Beta-Lactamase Inhibitor Emerging Drugs
Further product details are provided in the report……..
Beta-Lactamase Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Beta-Lactamase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Beta-Lactamase Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beta-Lactamase Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta-Lactamase Inhibitor drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Beta-Lactamase Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Beta-Lactamase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Beta-Lactamase Inhibitor: Overview
Beta-lactamases are an important group of bacterial enzymes, which preferentially cleave the beta-lactam ring of penicillins, cephalosporins, or other medically important beta-lactam antibiotics.
Function - Beta-lactamase provides antibiotic resistance by breaking the antibiotics' structure. These antibiotics all have a common element in their molecular structure: a four-atom ring known as a ?-lactam. Through hydrolysis, the enzyme lactamase breaks the ?-lactam ring open, deactivating the molecule's antibacterial properties.
Beta-Lactamase Inhibitors - Beta-lactamase inhibitors are drugs that are co-administered with beta-lactam antimicrobials to prevent antimicrobial resistance by inhibiting serine beta-lactamases, which are enzymes that inactivate the beta-lactam ring, which is a common chemical structure to all beta-lactam antimicrobials. This activity outlines the different types of beta-lactamase inhibitors.
Beta-Lactamase Inhibitor Emerging Drugs Chapters
This segment of the Beta-Lactamase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Beta-Lactamase Inhibitor Emerging Drugs
- Durlobactam/sulbactam: Entasis Therapeutics
- Ceftibuten/VNRX 7145: VenatoRx Pharmaceuticals
Further product details are provided in the report……..
Beta-Lactamase Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Beta-Lactamase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Beta-Lactamase Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Beta-Lactamase Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beta-Lactamase Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta-Lactamase Inhibitor drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Beta-Lactamase Inhibitor R&D. The therapies under development are focused on novel approaches for Beta-Lactamase Inhibitor.
- Beta-Lactamase Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Beta-Lactamase Inhibitor drugs?
- How many Beta-Lactamase Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Beta-Lactamase Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Beta-Lactamase Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Beta-Lactamase Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Entasis Therapeutics
- VenatoRx Pharmaceuticals
- Qpex Biopharma
- Boston Pharmaceuticals
- Merck Sharp and Dohme
- Fedora Pharmaceuticals
- Allecra Therapeutics
- AbbVie
- Arixa Pharmaceuticals
- LegoChem Biosciences
- Yuhan
- Allergan
- AstraZeneca
- Antabio
- Infex Therapeutics
- Durlobactam/sulbactam
- Ceftibuten/VNRX 7145
- QPX 7728
- BOS 572
- MK-7655A
- Nacubactam
- AAI-202
- ATM-AVI
- ARX 1796
- LCB18 0055
- YH-1177D
- CEF-104
- ANT2681
Introduction
Executive Summary
Beta-Lactamase Inhibitor: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Beta-Lactamase Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Beta-Lactamase Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Beta-Lactamase Inhibitor Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Durlobactam/sulbactam: Entasis Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
CEF-104 : Allergan
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
QPX 7728: Qpex Biopharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
LCB18 0055: LegoChem Biosciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Beta-Lactamase Inhibitor Key Companies
Beta-Lactamase Inhibitor Key Products
Beta-Lactamase Inhibitor- Unmet Needs
Beta-Lactamase Inhibitor- Market Drivers and Barriers
Beta-Lactamase Inhibitor- Future Perspectives and Conclusion
Beta-Lactamase Inhibitor Analyst Views
Beta-Lactamase Inhibitor Key Companies
Appendix
Executive Summary
Beta-Lactamase Inhibitor: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Beta-Lactamase Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Beta-Lactamase Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Beta-Lactamase Inhibitor Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Durlobactam/sulbactam: Entasis Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
CEF-104 : Allergan
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
QPX 7728: Qpex Biopharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
LCB18 0055: LegoChem Biosciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Beta-Lactamase Inhibitor Key Companies
Beta-Lactamase Inhibitor Key Products
Beta-Lactamase Inhibitor- Unmet Needs
Beta-Lactamase Inhibitor- Market Drivers and Barriers
Beta-Lactamase Inhibitor- Future Perspectives and Conclusion
Beta-Lactamase Inhibitor Analyst Views
Beta-Lactamase Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Beta-Lactamase Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Beta-Lactamase Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Beta-Lactamase Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Beta-Lactamase Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
